At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
BIBF 1120drug
Likely dose
BIBF 1120 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating BIBF 1120 for Ovarian Cancer and 2 related conditions. Completed, enrolled 32 participants across 3 sites.
Detailed Summary
The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsBoehringer Ingelheim
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartFeb 2013
Primary CompletionSep 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedAug 21, 2012
Enrollment StartFeb 1, 2013
Primary CompletionSep 10, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 13.9 years ago
Interventions
BIBF 1120drug
PO 200mg BID